top of page


Beyond the $100B Obesity Thesis: Decoding Incretins (GLP-1s) as Multi-Indication Longevity Infrastructure
The Valuation Re-Frame: From Consumer Diet Drug to Sovereign Infrastructure
Behind closed doors in institutional roundtables and private family office briefings, a fundamental valuation shift has occurred. The early narrative—dominated by direct-to-consumer weight-loss telehealth, consumer hype, and simple scale metrics—has run its course. Institutional allocators are now evaluating incretin receptor agonists through a far more rigorous lens: multi-systemic geroprotective pl
3 min read


The Gstaad Intelligence Brief: Where the Next $10B in Longevity Capital Will Flow
Direct macro intelligence synthesized from main-stage keynotes and private allocator dialogues at the seventh Longevity Investors Conference in Gstaad.
What Top Allocators at the Longevity Investors Conference Are Quietly Rotating Out Of—and the Sovereign Infrastructure Replacing It.
7 min read


Oura IPO Postponement: Tactical Delay Retains Longevity’s First Sovereign Asset Class
Oura Inc. (Nasdaq: OURA) sets its public market debut for the week of September 28, 2026, offering 50 million shares priced between $40.00 and $44.00 to target a fully diluted valuation of $15.62 billion.
Revenue scaled to $1.21 billion for the nine months ending June 30, 2026 (+74% YoY), driving a net income inflection to $60.8 million alongside expanding recurring SaaS margins.
3 min read
bottom of page




